|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> biodistribution studies showed high uptake of <sup>89</sup>Zr-DS-5573a in B7-H3-expressing MDA-MB-231 tumor-bearing mice, achieving 32.32 ± 6.55 %ID/g on day 7 post injection in BALB/c <i>nu</i>/<i>nu</i> mice and 25.76 ± 1.79 %ID/g in SCID mice, with minimal evidence of non-specific uptake in normal tissues, and excellent tumor localization on PET/MRI.
|
30128047 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor B7-H3 expression was significantly higher in immunocompetent vs. immunosuppressed patients, largely driven by very low expression in HIV+ patients.
|
29484464 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor cell B7-H3 expression was associated with increased disease-specific mortality in high FOXP3+ cell number group (hazard ratio [HR] =2.98; <i>P</i>=0.017), but not in low FOXP3+ group (<i>P</i>=0.71).
|
31440091 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 blockade promoted CD8(+) T-cell infiltration into the tumour and induced a substantial anti-tumour effect on murine pancreatic cancer.
|
19844235 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression was inversely correlated with the number of tumor infiltrating CD8+ T-cells (r=-0.4339, p=0.023).
|
21344157 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7H3 expression by tumor and endothelial cells correlates with the grade of malignancy in gliomas and with poor survival.
|
22080438 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 mRNA expression was positively associated with higher Gleason score (P<0.001), tumor stage (P<0.001), and castrate resistant metastatic disease (P<0.0001).
|
27801901 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 is an immune regulatory molecule whose aberrant expression in tumors is associated with adverse outcomes.
|
28627681 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3, a member of the B7 family, has been found with aberrant expression in tumors and infectious disease.
|
29423417 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3, a member of the B7 family of immunoregulatory proteins, is overexpressed in cancer and promotes tumor growth, metastasis, and drug resistance.
|
29860983 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression on tumor cells was positive in 92% of cases and 69% of controls.
|
30089601 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
|
30226585 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 is attractive for cancer immunotherapy with B7-H3 overexpressed tumors.
|
30253078 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 expression level was positively correlated with staining intensity of IBA1<sup>+</sup> cells, but negatively with T cell infiltration in CPs, suggesting that B7-H3 might play a role in the regulation of tumor microenvironment in CPs.
|
31043272 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 is overexpressed in a variety of tumor types, in correlation with poor prognosis.
|
31099317 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B7-H3 accelerates malignant proliferation by attacking the checkpoint mechanism of the tumor cell cycle through the phosphatidylinositol 3-kinase and protein kinase B pathway.
|
31222741 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B7-H3 expression was statistically correlated with patient gender (p = .0297), tumor histopathological subtypes (p = .0262) and radiotherapy after surgery (p = .0028).
|
31629137 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature.
|
28399405 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A small number of CD8<sup>+</sup> TILs was observed as a subpopulation with PD-L1 tumor proportion score less than 50%, whereas CD8<sup>+</sup> TILs were still abundant in tumors not expressing B7-H3.
|
29530936 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
According to the information mined from the tumor gene database, CD276 mRNA was found highly expressed in NSCLC tissue and the expression of CD276 has a significant impact on survival of NSCLC patients, which provides an important theoretical basis for further study of the role of CD276 in the occurrence and development of NSCLC.
|
31737785 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
According to the results, B7-H3 is highly expressed in the tumor vascular endothelium of ccRCC and is associated with the ccRCC grade and tumor-node-metastasis (TNM) stage.
|
29180874 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
An abnormal high expression of B7-H3 molecules is often observed in tumor cells and tumor stromal cells in the tumor microenvironment.
|
31213832 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By means of a highly physiologic, spontaneous tumor model in mice, we establish a causal link between B7-H3 and host tumor control and found B7-H4 to be redundant.
|
26122284 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined <i>in vitro/in vivo</i> imaging showed that sPA allowed specific B7-H3-ICG detection down to the 13 nM concentration and differentiation from Iso-ICG. sPA molecular imaging of B7-H3-ICG showed a 3.01-fold (P<0.01) increase in molecular B7-H3-ICG signal in tumors compared to control conditions.
|
28529630 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with control microbubbles, the ultrasound signal using CD276-targeted microbubbles was significantly higher (P = 0.002), and blocking with purified anti-CD276 antibody significantly decreased (P = 0.0096) the signal in mixed MS1/2008 tumors.
|
24389327 |
2014 |